Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesZai Lab Ltd

Zai Lab Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
22.84 USD 0.88 ( 4.01%)
Last update at 2026-11-04T20:57:00Z
VOLUME
719803
Market Cap
2806.66M

Momentum Score

…

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
22.26
Low
23.40
High
52 Week Price Range
15.96
Low
34.72
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
21.96
Dividend Yield
-
Revenue TTM
449.61M
Revenue Per Share
4.06
Gross Profit TTM
16.98M
Debt / Equity
0.31
ROE
-26.91%
Net Debt
-455.31M
ROCE
-22.91%
Diluted EPS TTM
-1.70

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -178.46M -257.10M -334.62M -443.06M -703.41M
Net income -175.54M -257.10M -334.62M -481.99M -692.44M
Selling general administrative 277.61M 298.74M 281.61M 258.97M 218.83M
Gross profit 269.07M 251.13M 170.90M 141.02M 92.07M
Reconciled depreciation 15.01M 11.86M 8.70M 8.23M 6.49M
Ebit -173.25M -254.85M -374.14M -404.36M -700.06M
Ebitda -158.25M -234.57M -365.11M -386.66M -703.41M
Depreciation and amortization 15.01M 20.27M 9.03M 17.70M -3.35M
Operating income -223.57M -282.12M -366.57M -404.36M -700.06M
Other operating expenses 683.73M 681.11M 633.29M 619.40M 844.38M
Interest expense 5.21M 2.25M 14.58M 14.58M 3.35M
Tax provision -2.93M 0.00M 0.00M 0.00M 0.00M
Interest income 33.05M 37.10M 38.84M 14.58M 2.19M
Net interest income 27.84M 34.85M 38.84M 14.58M 2.19M
Income tax expense -2.93M - 38.93M 38.93M -10.97M
Total revenue 460.16M 398.99M 266.72M 215.04M 144.31M
Total operating expenses 492.65M 533.25M 537.48M 545.38M 792.14M
Cost of revenue 191.08M 147.86M 95.82M 74.02M 52.24M
Total other income expense net 45.11M 25.01M 31.95M -38.71M -3.35M
Net income from continuing ops -175.54M -257.10M -300.96M -443.29M -704.47M
Net income applicable to common shares - - - -443.29M -704.47M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1172.38M 1185.75M 1036.30M 1220.14M 1609.96M
Intangible assets 76.14M 58.93M 16.46M 8.40M 9.66M
Other current assets 148.85M 141.53M 23.00M 35.67M 18.02M
Total liab 456.88M 344.86M 240.18M 174.54M 230.00M
Total stockholder equity 715.50M 840.90M 796.12M 1045.60M 1379.96M
Other current liab 63.68M 53.57M 54.23M 45.46M 33.33M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -2628.62M -2453.08M -2195.98M -1861.36M -1418.07M
Other liab - - - 21.36M 27.49M
Other assets - - - 3.60M 26.52M
Cash 679.57M 449.67M 790.15M 1008.47M 964.10M
Total current liabilities 416.17M 299.38M 203.07M 139.84M 192.90M
Current deferred revenue 27.33M 31.43M 28.74M 21.36M 27.49M
Net debt -455.31M -296.20M -775.00M -988.08M -948.56M
Short term debt 210.87M 139.76M 7.10M 7.05M 5.93M
Short long term debt 204.53M 131.71M - - -
Short long term debt total 224.26M 153.47M 15.15M 20.39M 15.54M
Other stockholder equity 3314.42M 3243.46M 2954.47M 2881.26M 2821.67M
Property plant equipment - - - 77.38M 57.29M
Total current assets 1019.29M 1050.48M 939.61M 1124.34M 1500.88M
Long term investments - 3.12M 9.22M 6.43M 15.61M
Net tangible assets - - - 1037.19M 1370.30M
Short term investments 10.00M 330.00M 16.30M 0.00M 445.00M
Net receivables 106.12M 89.41M 65.33M 48.57M 54.81M
Inventory 74.75M 39.88M 44.83M 31.62M 18.95M
Accounts payable 141.61M 100.91M 112.99M 65.97M 126.16M
Accumulated other comprehensive income 29.70M 50.52M 37.63M 25.68M -23.64M
Non currrent assets other 7.02M 3.75M 4.28M 2.20M 0.80M
Non current assets total 153.10M 135.27M 96.69M 95.80M 109.08M
Capital lease obligations 19.73M 21.76M 15.15M 20.39M 15.54M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 321.20M -375.19M -29.61M 420.02M 268.90M
Change to liabilities - - - -55.15M 74.67M
Total cashflows from investing activities 307.87M -375.19M -10.78M 420.02M 249.96M
Net borrowings 67.94M 131.32M 0.00M - -
Total cash from financing activities 72.35M 349.89M -6.43M -1.73M 820.20M
Change to operating activities - - - -0.04M -2.07M
Net income -175.54M -257.10M -334.62M -443.29M -704.47M
Change in cash 229.91M -240.48M -218.01M 44.37M 522.04M
Begin period cash flow 550.78M 791.26M 1009.27M 964.90M 442.86M
End period cash flow 780.69M 550.78M 791.26M 1009.27M 964.90M
Total cash from operating activities -150.79M -214.87M -198.18M -367.64M -549.23M
Issuance of capital stock 0.00M 217.35M 0.00M 0.00M 818.88M
Depreciation 15.01M 11.86M 9.03M 8.23M 6.49M
Other cashflows from investing activities -5.24M -55.86M 12.74M - -
Change to inventory -47.03M 3.90M -14.91M -15.38M -7.17M
Change to account receivables -29.98M -26.58M -17.69M 4.33M -42.32M
Sale purchase of stock - - -8.80M - -
Other cashflows from financing activities -9.27M 1.22M -6.43M -7.60M 1.33M
Change to netincome - - - 133.66M 125.64M
Capital expenditures 13.42M 61.52M 8.49M 24.98M 18.95M
Change in working capital -54.71M -68.39M 39.61M -66.25M 23.11M
Stock based compensation 65.60M 70.65M 79.63M 61.30M 40.71M
Other non cash items -1.15M 28.12M 8.17M 72.36M 67.85M
Free cash flow -164.21M -276.39M -206.67M -392.63M -568.18M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ZLAB
Zai Lab Ltd		 0.88
4.01%		 22.84 - - 6.24 4.55 5.23 -2.35
NVO
Novo Nordisk A/S		 1.99
4.95%		 42.18 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 18.28
3.44%		 549.04 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -41.91
4.31%		 931.45 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Zai Lab Ltd

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

Building B, Pudong, China, 201203

86 21 6163 2588

https://www.zailaboratory.com

1784

Name Title Year Born
Dr. Ying Du Ph.D. Founder, Chairperson & CEO 1966
Mr. Ki Chul Cho Chief Financial Officer 1978
Mr. Frazor Titus Edmondson III Chief Legal Officer & Corp. Sec. 1966
Dr. Harald Reinhart M.D. Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases 1952
Mr. Joshua L. Smiley Chief Operating Officer 1970
Dr. Peter Huang Ph.D. Chief Scientific Officer NA
Ms. Ann E. Beasley J.D. Chief Compliance Officer NA
Dr. Ning Xu M.D. Exec. VP & Head of Clinical Operations 1965
Dr. Jonathan J. Wang M.B.A., MBA, Ph.D. Chief Bus. Officer 1982
Dr. James Yan DABT, M.D., Ph.D. Chief Operating Officer of R&D 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…